Short Interest in Repare Therapeutics Inc. (NASDAQ:RPTX) Grows By 53.3%

Repare Therapeutics Inc. (NASDAQ:RPTX) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 1,300,000 shares, an increase of 53.3% from the December 15th total of 847,800 shares. Approximately 4.3% of the company’s stock are short sold. Based on an average trading volume of 380,100 shares, the days-to-cover ratio is presently 3.4 days.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on RPTX shares. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Repare Therapeutics in a research report on Friday, November 8th. Bloom Burton cut shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th. Lifesci Capital restated a “market perform” rating on shares of Repare Therapeutics in a research note on Friday, December 13th. Finally, Stifel Nicolaus dropped their price target on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 13th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its stake in Repare Therapeutics by 30.7% in the second quarter. Renaissance Technologies LLC now owns 458,700 shares of the company’s stock valued at $1,514,000 after purchasing an additional 107,700 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Repare Therapeutics in the second quarter valued at $110,000. Bank of Montreal Can lifted its position in shares of Repare Therapeutics by 5.4% during the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock valued at $366,000 after buying an additional 5,673 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Repare Therapeutics during the 2nd quarter valued at $273,000. Finally, Squarepoint Ops LLC grew its stake in shares of Repare Therapeutics by 428.4% during the 2nd quarter. Squarepoint Ops LLC now owns 142,974 shares of the company’s stock worth $472,000 after acquiring an additional 115,916 shares during the period. 85.09% of the stock is owned by institutional investors.

Repare Therapeutics Price Performance

NASDAQ RPTX remained flat at $1.28 during trading hours on Friday. 189,282 shares of the company were exchanged, compared to its average volume of 500,189. The company has a market cap of $54.41 million, a PE ratio of -0.64 and a beta of 0.88. Repare Therapeutics has a 1-year low of $1.20 and a 1-year high of $8.49. The firm has a 50-day simple moving average of $2.28 and a 200 day simple moving average of $2.97.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.